Greenwich Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Greenwich Wealth Management's REGN Position: Q2 2026 in Review
Greenwich Wealth Management reduced its Regeneron Pharmaceuticals (REGN) stake by 0.05% in Q2 2026, selling an estimated $5.45K and leaving 16,094 shares worth $10M. The position accounts for 0.37% of the portfolio, ranked #48.
Greenwich Wealth Management first reported a position in REGN in Q1 2020 and has held it in 26 quarters since. The position peaked at $16.9M in Q2 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Greenwich Wealth Management held 16,094 shares of Regeneron Pharmaceuticals worth $10M as of Q2 2026.
- Greenwich Wealth Management sold 8 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $5.45K.
- Regeneron Pharmaceuticals made up 0.37% of Greenwich Wealth Management's portfolio in Q2 2026, its #48 holding.
- Greenwich Wealth Management first reported a position in Regeneron Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
- Greenwich Wealth Management's Regeneron Pharmaceuticals position peaked at $16.9M in Q2 2024.
- 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Greenwich Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.